Related Experiment Videos
Expression of active human factor VIII from recombinant DNA clones
Nature
|November 22, 1984
Summary
Scientists created biologically active human factor VIII using DNA clones in mammalian cells. This recombinant factor VIII corrects clotting times in haemophiliac plasma, matching serum-derived factor VIII characteristics.
Area of Science:
- Biochemistry
- Molecular Biology
- Hematology
Background:
- Hemophilia A is a severe bleeding disorder caused by deficiency in coagulation factor VIII.
- Current treatments rely on factor VIII derived from human plasma, posing risks of pathogen transmission.
Purpose of the Study:
- To produce biologically active recombinant human factor VIII (rhFVIII) using gene cloning.
- To characterize the biochemical and immunological properties of rhFVIII.
- To assess the efficacy of rhF উপলব্ধি in correcting clotting times in hemophilic plasma.
Main Methods:
- Isolation of DNA clones encoding the complete 2,351 amino acid sequence of human factor VIII.
- Expression of recombinant human factor VIII in cultured mammalian cells.
- Biochemical and immunological characterization of the recombinant protein.
- Assessment of clotting factor activity in hemophilic plasma.
Main Results:
- Successful production of biologically active recombinant human factor VIII.
- The recombinant protein demonstrated efficacy in correcting the clotting time of plasma from hemophiliacs.
- Biochemical and immunological profiles of rhFVIII were comparable to serum-derived factor VIII.
Conclusions:
- Recombinant human factor VIII can be produced effectively in mammalian cell cultures.
- rhFVIII holds potential as a safe and effective therapeutic alternative for hemophilia A treatment.
- This advancement offers a promising avenue for improving hemophilia management.